A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome

Journal of Clinical Biochemistry and Nutrition

Volumn 62, Issue 2, 2018, Pages 179-186

  Shin, Suk Pyo ^a   Choi, Yoon Mi ^b   Kim, Won Hee ^b   Hong, Sung Pyo ^b   Park, Jong Min ^c   Kim, Joohee ^d   Kwon, Oran ^d   Lee, Eun Hyun ^e   Hahm, Ki Baik ^b,c  

^a Hallym University   (South Korea)

^b CHA University   (South Korea)

^c CHA Bio Complex CHA Cancer Prevention Research Center   (South Korea)

^d Ewha Womans University   (South Korea)

^e Ajou University   (South Korea)

Author keywords

Colon transit time; Diarrhea dominant IBS; IBS QOL; Lactobacillus gasseri BNR17; Microbiota

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; PROBIOTIC AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BREAST MILK; COLLINSELLA AEROFACIENS; CONTROLLED STUDY; DEFECATION; DIARRHEA; DIARRHEA DOMINANT IRRITABLE BOWEL SYNDROME; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; FECES MICROFLORA; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE TRANSIT TIME; IRRITABLE COLON; LACTOBACILLUS GASSERI; LACTOBACILLUS GASSERI BNR17; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 85043492165     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.17-73     Document Type: Article

References (41)

1. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 2011; 45 Suppl: S149-S153.
2. Issa I, Moucari R. Probiotics for antibiotic-associated diarrhea: do we have a verdict?. World J Gastroenterol 2014; 20: 17788-17795.
3. Guandalini S, Cernat E, Moscoso D. Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children. Benef Microbes 2015; 6: 209-217.
4. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 2013; 29: 184-189.
5. Yoon H, Park YS, Lee DH, Seo JG, Shin CM, Kim N. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr 2015; 57: 129-134.
6. Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig 2014; 34: 783-793.
7. Monnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol 2011; 45 Suppl: S98-S101.
8. Park JM, Choi MG, Kim YS, et al. Quality of life of patients with irritable bowel syndrome in Korea. Qual Life Res 2009; 18: 435-446.
9. Ma AD, Kessler CM, Al-Mondhiry HA, Gut RZ, Cooper DL. Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study. Blood Coagul Fibrinolysis 2016; 27: 753-760.
10. Ishimoto H, Oshima T, Sei H, et al. Claudin-2 expression is upregulated in the ileum of diarrhea predominant irritable bowel syndrome patients. J Clin Biochem Nutr 2017; 60: 146-150.
11. Belkind-Gerson J, Tran K, Di Lorenzo C. Novel techniques to study colonic motor function in children. Curr Gastroenterol Rep 2013; 15: 335.
12. Biedermann L, Rogler G. The intestinal microbiota: its role in health and disease. Eur J Pediatr 2015; 174: 151-167.
13. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946-953.
14. Kang JH, Yun SI, Park HO. Effects of Lactobacillus gasseri BNR17 on body weight and adipose tissue mass in diet-induced overweight rats. J Microbiol 2010; 48: 712-714.
15. Kang JH, Yun SI, Park MH, Park JH, Jeong SY, Park HO. Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. PLoS One 2013; 8: e54617.
16. Jung SP, Lee KM, Kang JH, et al. Effect of Lactobacillus gasseri BNR17 on overweight and obese adults: a randomized, double-blind clinical trial. Korean J Fam Med 2013; 34: 80-89.
17. Lee EH, Kwon O, Hahm KB, et al. Irritable bowel syndrome-specific health-related quality of life instrument: development and psychometric evaluation. Health Qual Life Outcomes 2016; 14: 22.
18. Rondanelli M, Faliva MA, Perna S, Giacosa A, Peroni G, Castellazzi AM. Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses. Gut Microbes 2017. DOI: 10.1080/19490976.2017.1345414
19. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475-486.
20. Lorenzo-Zúñiga V, Llop E, Suárez C, et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol 2014; 20: 8709-8716.
21. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 1123-1132.
22. Guandalini S, Magazzù G, Chiaro A, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 2010; 51: 24-30.
23. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000; 32: 294-301.
24. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 2615-2620.
25. Newcomer AD, Park HS, O'Brien PC, McGill DB. Response of patients with irritable bowel syndrome and lactase deficiency using unfermented acidophilus milk. Am J Clin Nutr 1983; 38: 257-263.
26. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 925-931.
27. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011; 45: 679-683.
28. Kabir MA, Ishaque SM, Ali MS, Mahmuduzzaman M, Hasan M. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome. Mymensingh Med J 2011; 20: 397-401.
29. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005; 17: 332-340.
30. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20 Suppl 2: 1-9.
31. Corbett CL, Thomas S, Read NW, Hobson N, Bergman I, Holdsworth CD. Electrochemical detector for breath hydrogen determination: measurement of small bowel transit time in normal subjects and patients with the irritable bowel syndrome. Gut 1981; 22: 836-840.
32. Lu WZ, Song GH, Gwee KA. Ho KY. The effects of melatonin on colonic transit time in normal controls and IBS patients. Dig Dis Sci 2009; 54: 1087-1093.
33. Horikawa Y, Mieno H, Inoue M, Kajiyama G. Gastrointestinal motility in patients with irritable bowel syndrome studied by using radiopaque markers. Scand J Gastroenterol 1999; 34: 1190-1195.
34. Lee OY. Asian motility studies in irritable bowel syndrome. J Neurogastroenterol Motil 2010; 16: 120-130.
35. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-696.
36. Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 2014; 20: 8886-8897.
37. Jeffery IB, O'Toole PW, Öhman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997-1006.
38. Rajilić-Stojanović M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-1801.
39. Krogius-Kurikka L, Lyra A, Malinen E, et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9: 95.
40. Yun SI, Park HO, Kang JH. Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. J Appl Microbiol 2009; 107: 1681-1686.
41. Bouchoucha M, Nalpas B, Berger M, Cugnenc PH, Barbier JP. Recovery from disturbed colonic transit time after alcohol withdrawal. Dis Colon Rectum 1991; 34: 111-114.